Literature DB >> 14516487

Tentative identification of novel oxycodone metabolites in human urine.

Karla A Moore1, Vera Ramcharitar, Barry Levine, David Fowler.   

Abstract

Oxycodone is a semisynthetic codeine derivative that has been used both as an analgesic and antitussive. In the mid 1990s, OxyContin was introduced as a slow-release formulation of oxycodone for use in patients with moderate to severe chronic pain from such ailments as arthritis, vertebral disc disease, and cancer. Doctors wrote 6.9 million prescriptions for OxyContin from May 2000 through May 2001. Thus, it is no surprise that hospitals and medical examiners' offices across the country have seen an increasing number of admissions and deaths resulting from oxycodone abuse and overdose. The laboratory identifies oxycodone as part of its routine abused and therapeutic drug-testing procedures. Routine gas chromatographic analysis of bile or urine in many of these cases revealed unidentified peaks in the region of oxycodone that appeared to be oxycodone metabolites. In humans, the only documented metabolites of oxycodone are oxymorphone and N-desmethyloxycodone (noroxycodone). This study attempts to characterize these compounds as "presumptive" metabolites based on circumstantial evidence from known metabolic pathways of oxycodone in other species, as well as of other opiates and narcotic analgesics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14516487     DOI: 10.1093/jat/27.6.346

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  7 in total

1.  Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?

Authors:  Bruce Charles; Janet Hardy; Helen Anderson; Angela Tapuni; Rani George; Ross Norris
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

2.  Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.

Authors:  Wenfang B Fang; Michelle R Lofwall; Sharon L Walsh; David E Moody
Journal:  J Anal Toxicol       Date:  2013-06-05       Impact factor: 3.367

3.  Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.

Authors:  Trine Naalsund Andreassen; Pål Klepstad; Andrew Davies; Kristin Bjordal; Staffan Lundström; Stein Kaasa; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2010-12-08       Impact factor: 2.953

4.  Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study.

Authors:  Trine Naalsund Andreassen; Ingrid Eftedal; Pål Klepstad; Andrew Davies; Kristin Bjordal; Staffan Lundström; Stein Kaasa; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2011-07-07       Impact factor: 2.953

5.  Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model.

Authors:  N Marsousi; Y Daali; S Rudaz; L Almond; H Humphries; J Desmeules; C F Samer
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-12-17

6.  Electrochemical Detection of Oxycodone and Its Main Metabolites with Nafion-Coated Single-Walled Carbon Nanotube Electrodes.

Authors:  Elsi Mynttinen; Niklas Wester; Tuomas Lilius; Eija Kalso; Bjørn Mikladal; Ilkka Varjos; Sami Sainio; Hua Jiang; Esko I Kauppinen; Jari Koskinen; Tomi Laurila
Journal:  Anal Chem       Date:  2020-05-28       Impact factor: 6.986

7.  The Quantification of Oxycodone and Its Phase I and II Metabolites in Urine.

Authors:  Michael T Truver; Gerd Jakobsson; Maria D Chermà; Madeleine J Swortwood; Henrik Gréen; Robert Kronstrand
Journal:  J Anal Toxicol       Date:  2022-02-14       Impact factor: 3.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.